Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

IJC Heart & Vasculature is a premier open-access journal published by Elsevier Ireland Ltd, dedicated to advancing research in the fields of cardiology and cardiovascular medicine. Since its inception in 2013, this journal has established itself as a valuable resource for clinicians, researchers, and students keen on exploring the latest developments in heart and vascular health. With an impressive impact factor and ranked within Q2 in its category (2023), IJC Heart & Vasculature has achieved a significant Scopus rank of #125 out of 387, placing it in the 67th percentile of cardiology journals. The journal not only emphasizes high-quality research but also promotes innovative studies that can shape clinical practices and improve patient outcomes. Researchers and professionals can access a plethora of peer-reviewed articles, original research, and comprehensive reviews that unravel the complexities of cardiovascular science. With a commitment to fostering open and impactful dialogue in the field, IJC Heart & Vasculature is poised to be an essential platform for knowledge exchange in the evolving landscape of cardiovascular research.

Welcome to the International Journal of Angiology, a distinguished publication dedicated to advancing the field of cardiology and cardiovascular medicine. Published by THIEME MEDICAL PUBL INC, this journal plays a crucial role in disseminating innovative research and clinical insights from 1992 through 2024, serving as a vital resource for researchers, healthcare professionals, and students alike. With an ISSN of 1061-1711 and an E-ISSN of 1615-5939, the journal currently holds a respectable Q4 ranking in the cardiology field, reflecting its commitment to quality and relevance. Although it operates under a traditional access model, the journal ensures that critical research findings are shared with a broad audience, fostering collaboration and knowledge exchange. By exploring current trends, diagnostic techniques, and treatment modalities in angiology, the International Journal of Angiology remains an essential platform for those dedicated to improving cardiovascular health around the globe.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

CARDIOLOGY, published by KARGER, is a renowned scholarly journal dedicated to the advancement of research in the fields of cardiology and cardiovascular medicine. Since its inception in 1937, the journal has consistently provided a platform for high-quality, peer-reviewed articles that contribute to the understanding and treatment of heart and vascular diseases. With an impressive convergence through 2024, CARDIOLOGY holds a respectable Q2 ranking in both the Cardiology and Cardiovascular Medicine and Pharmacology (medical) categories, placing it within the 53rd and 45th percentiles of respective Scopus ranks. Based in Switzerland, the journal serves as an essential resource for researchers and practitioners aiming to stay abreast of cutting-edge developments and evidence-based practices in cardiovascular health. While it currently does not offer open access options, its commitment to rigorous scientific standards solidifies its significance within the academic community. We invite readers to explore the latest research findings and contribute to this vital field through publications in CARDIOLOGY.

Cardiovascular Innovations and Applications is a premier open-access journal dedicated to advancing knowledge in the field of cardiovascular medicine. Published by COMPUSCRIPT since 2016, this journal provides a platform for the dissemination of innovative research and applications that address crucial topics in cardiology, aiming to bridge the gap between clinical practice and cutting-edge research. With an ISSN of 2009-8618 and an E-ISSN of 2009-8782, it operates on a global scale, facilitating access to high-quality content without financial barriers. The journal is positioned within the Medicine - Cardiology and Cardiovascular Medicine category, and its current Scopus rank of #321/387 reflects its potential for growth and influence in the academic community, being in the 17th percentile. Researchers, healthcare professionals, and students will find Cardiovascular Innovations and Applications an invaluable resource in their quest for the latest findings and advancements in cardiovascular health and treatment methodologies.

The American Journal of Cardiology is a leading peer-reviewed journal in the field of Cardiology and Cardiovascular Medicine, published by Excerpta Medica Inc-Elsevier Science Inc. Since its inception in 1958, the journal has consistently contributed to the advancement of cardiovascular research, providing a platform for groundbreaking studies and clinical findings that shape modern medical practices. With an impressive impact factor placing it in the Q1 category in its field for 2023, it ranks among the top journals in medicine, with a rank of #155 out of 387 in the Scopus database, reflecting its significance and rigorous editorial standards. The journal is committed to disseminating high-quality research that fosters innovation and enhances clinical outcomes in cardiology. Although it does not provide Open Access options, the American Journal of Cardiology remains an essential resource for researchers, healthcare professionals, and students looking to deepen their understanding of cardiovascular health.

BMC Cardiovascular Disorders is a premier open access journal dedicated to the field of cardiology and cardiovascular medicine, published by BMC, a leading publisher in the scientific community. Since its inception in 2001, this journal has provided a platform for high-quality research, showcasing innovative studies and critical reviews that contribute to the understanding and management of cardiovascular diseases. With an impressive impact factor and a rank in the Q2 category for 2023 within its field, BMC Cardiovascular Disorders stands at the forefront of cardiovascular research, enabling accessibility to a wealth of information that fosters collaboration and advancements in patient care. The journal's commitment to open access ensures that research is widely disseminated and easily accessible to researchers, practitioners, and students globally, enhancing the dialogue around cardiovascular health and disease prevention. Located in the United Kingdom, BMC Cardiovascular Disorders consistently aims to promote excellence in the study and treatment of cardiovascular conditions, encouraging the exchange of knowledge that ultimately benefits public health.

Frontiers in Cardiovascular Medicine is a leading open-access journal published by FRONTIERS MEDIA SA, dedicated to advancing research in the field of cardiology and cardiovascular medicine. Since its inception in 2014, the journal has become a vital platform for the dissemination of high-quality research, boasting a commendable Q2 rank in the 2023 category for Cardiology and Cardiovascular Medicine. With a focus on promoting innovative studies and clinical insights, Frontiers in Cardiovascular Medicine facilitates open access to its content, allowing researchers, healthcare professionals, and students from around the globe to engage with the latest findings which are critical for the advancement of cardiovascular health. The journal's significant presence in the academic landscape, as indicated by its Scopus ranking (161/387 and 58th percentile), underscores its importance as a research outlet in this essential field. Located in Lausanne, Switzerland, the journal continues to support the global cardiovascular community by encouraging collaboration and knowledge sharing to address the challenges faced in cardiovascular medicine today.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.